Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.61 |
| ▸ | CCR5 | P51681 | 1/20 | 0.61 |
| ▸ | CCR8 | P51685 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | BCR | P11274 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31695263 | 0.89 | CCR1 (0.76) | CCR1CCR5CCR8CYP2A6NPC1 | |
| SCHEMBL27344644 | 0.89 | CCR1 (0.76) | CCR1CCR5CCR8CYP2A6NPC1 | |
| SCHEMBL29463685 | 0.85 | CCR1 (0.70) | CCR1CCR5CCR8CYP2A6NPC1 | |
| SCHEMBL6807225 | 0.85 | CCR1 (0.70) | CCR1CCR5CCR8CYP2A6NPC1 | |
| SCHEMBL19248539 | 0.84 | CCR1 (0.61) | CCR1CCR5CCR8CYP2A6NPC1 | |
| SCHEMBL2666352 | 0.81 | CCR1 (0.57) | CCR1CCR5CCR8CYP2A6RAB9A | |
| SCHEMBL14082326 | 0.80 | PTPN1 (0.64) | NPC1RAB9AMEN1KMT2AABL1 | |
| SCHEMBL2190158 | 0.80 | CYP2A6 (0.62) | CCR1CCR5CCR8CYP2A6NPC1 | |
| SCHEMBL17406767 | 0.80 | CCR1 (0.61) | CCR1CCR5CCR8CYP2A6NPC1 | |
| SCHEMBL5956691 | 0.80 | CCR1 (0.61) | CCR1CCR5CCR8CYP2A6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143253-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| EP-2183027-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204235-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | US | disclosed |
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| CN-1135227-C | 2,6-twice substituted pyridine and 2,4-twice substituted pyrimidine for berbicide | 谷 | 2004-01-21 | — | — | CN | disclosed |
| EP-1355903-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | disclosed |
| EP-1355870-A1 | THIAZOLAMINES AND THEIR USE AS TGF-BETA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002066462-A1 | PYRAZOLE DERIVATIVES AGAINST TGF OVEREXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002062753-A1 | THIAZOLAMINES AND THEIR USE AS TGF-BETA INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
| US-6090812-A | THERAPY FOR PSYCHOLOGICAL, CENTRAL NERVOUS SYSTEM DISORDERS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2000-07-18 | — | — | US | disclosed |
| EP-0908458-A1 | Substituted pyridylmethylpiperazine and -piperidine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1999-04-14 | — | — | EP | disclosed |
| CN-1143078-A | 2,6-twice substituted pyridine and 2,4-twice substituted pyrimidine for berbicide | AMERICAN CYANAMID CO (US) | 1997-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | CCR1 202/4885CCR5 170/4885CCR8 361/4885 |
| US-20100204235-A1 | ORGANIC COMPOUNDS | ALK, OR10J3, FFAR4 | CCR1 368/4885CCR5 247/4885CCR8 523/4885 |
| US-20040077687-A1 | Thiazolmines and their use as tgf-beta inhibitors | TGFBR1, TGFB1, TGFBR2 | CCR1 509/4885CCR5 1105/4885CCR8 1652/4885 |
| US-20040087623-A1 | Pyrazole derivatives against tgf overexpression | TGFBR1, SMAD3, TGFBR2 | CCR1 824/4885CCR5 1748/4885CCR8 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.